Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines

Clinical Cancer Research

Volumn 7, Issue 8, 2001, Pages 2581-2589

  Robinson, B W ^a   Shewach, D S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; GEMCITABINE; PROTEIN P53;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL SURVIVAL; DEOXYADENINE NUCLEOTIDES; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, RADIATION; GENOTYPE; HUMANS; MUTATION; RADIATION-SENSITIZING AGENTS; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034890643     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
2. Clinical update of gemcitabine in pancreas cancer
3. New agents in gastrointestinal malignancies: Part 2. Gemcitabine in clinical practice
4. Chemotherapy in the treatment of cancer of the pancreas
5. Gemcitabine: A new approach to treating pancreatic cancer
6. Activity of gemcitabine in patients with non-small cell lung cancer: A multicenter extended Phase II study
7. Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small-cell lung cancer: An overview
8. Gemcitabine as second-line treatment for advanced non-small cell lung cancer: A Phase II trial
9. Single-agent gemcitabine as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Phase II trial
10. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: Results of an Argentinean multicentre Phase II trial
11. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: The Central European Phase II study
12. Activity of gemcitabine in non-small-cell lung cancer: Results of the Japan gemcitabine group (A) Phase II study
13. Radiosensitization of pancreatic cancer cells by 2′,2′difluoro-2′-deoxycytidine
14. Radiosensitizing nucleosides
15. Metabolism of 2′,2′-difluorodeoxycytidine and radiation sensitization of human colon carcinoma cells
16. Kinetics of mouse jejunum radiosensitization by 2′,2′-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells
17. Radiosensitization produced in vivo by once- versus twice-weekly 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)
18. 3H mice
19. Gemcitabine: A pharmacologic and clinical overview
20. Gemcitabine: A cytidine analogue active against solid tumors
21. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine
22. 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: Potent mechanism-based inhibitors of ribonucleotide reductase
23. Action of 2′,2′-diflourodeoxycytidine on DNA synthesis
24. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumor cell lines
25. Radiosensitization of Chinese hamster V79 cells by bromodeoxyuridine substitution of thymidine: Enhancement of radiation-induced toxicity and DNA strand break production by monofilar and bifilar substitution
26. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. I. Radiosensitization of human colon cancer cells by iododeoxyuridine
27. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. II. Radiosensitization of human colon cancer cells by bromodeoxyuridine
28. Mechanism of radiosensitization by halogenated pyrimidines: Bromodeoxyuridine and α-arabinofuranosyladenine affect similar subsets of radiation-induced potentially lethal lesions in plateau-phase Chinese hamster ovary cells
29. Mechanism of radiosensitization by halogenated pyrimidines: Effect of BrdU on radiation induction of DNA and chromosome damage and its correlation with cell killing
30. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)
31. Radiosensitization of human tumor cells by gemcitabine in vitro
32. Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro
33. The role of cell cycle progression in radiosensitization by 2′,2′-difluoro-2′-deoxycytidine
34. The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization
35. Gemcitabine and radiosensitization in human tumor cells
36. Gemcitabine: Its role in radiosensitization and cell cycle progression with two human breast carcinoma cell lines
37. Mean inactivation dose: A useful concept for intercomparison of human cell survival curves
38. Quantitation of deoxyribonucleoside 5′-triphosphates by a sequential boronate and anion-exchange high-pressure liquid chromatographic procedure
39. Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): Critical factors that affect the amount of fluorescence and the shape of BrdUrd/DNA histogram
40. Cytokinetic properties of asynchronous and cytosine arabinoside perturbed murine tumors measured by simultaneous bromodeoxyuridine/DNA analyses
41. Tumor-suppressor p53: Implications for tumor development and prognosis
42. Cancer: p53 sends nucleotides to repair DNA
43. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
44. Medical progress: Clinical implications of the p53 tumor-suppressor gene
45. Database of p53 gene somatic mutations in human tumors and cell lines
46. p53 mutations in human cancers
47. Life (and death) in a malignant tumour
48. Isolation of amplified and overexpressed DNA sequences from Adriamycin-resistant human breast cancer cells
49. Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors
50. Ascorbic acid and cell survival of resistant and sensitive MCF-7 breast tumor cells
51. Gemcitabine cytotoxicity of human malignant glioma cells: Modulation by antioxidants, BCL-2, and dexamethasone
52. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells
53. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline
54. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma
55. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
56. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: A Phase I trial and intracellular drug incorporation study